CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-23 | Bhavnagri Veer General Counsel | Grant or award · Stock Option (Right to Buy) | +272,435 | 272,435 | ||
| 2022-03-15 | Amado Rafael EVP of R&D and CMO | Sale | −5,169 | $7.71 | $40K | 320,119 |
| 2022-03-15 | Bhavnagri Veer General Counsel | Sale | −8,849 | $7.68 | $68K | 413,841 |
| 2022-03-15 | Chang David D President and CEO | Sale | −23,648 | $7.65 | $181K | 2,289,652 |
| 2022-03-15 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −11,469 | $7.63 | $88K | 100,546 |
| 2022-03-15 | MOORE ALISON Chief Technical Officer | Sale | −8,698 | $7.63 | $66K | 120,430 |
| 2022-03-14 | Belldegrun Arie Director | Other disposition | −4,710,120 | 0 | ||
| 2022-03-14 | Belldegrun Arie Director | Other acquisition | +4,710,120 | 4,710,120 | ||
| 2022-03-14 | Belldegrun Arie Director | Other disposition | −4,710,121 | 0 | ||
| 2022-03-14 | Belldegrun Arie Director | Other acquisition | +4,710,121 | 4,710,121 | ||
| 2022-03-07 | Kazam Joshua A Director | Other acquisition | +412,618 | 671,503 | ||
| 2022-03-07 | Kazam Joshua A Director | Gift | −412,618 | 258,885 | ||
| 2022-01-12 | Kazam Joshua A Director | Purchase | +15,000 | $12.60 | $189K | 258,885 |
| 2022-01-12 | Belldegrun Arie Director | Purchase | +155,039 | $12.60 | $2.0M | 195,039 |
| 2021-10-01 | Amado Rafael EVP of R&D and CMO | Sale | −11,507 | $24.35 | $280K | 323,928 |
| 2021-09-15 | Bhavnagri Veer General Counsel | Option exercise | +5,000 | $2.27 | $11K | 426,669 |
| 2021-09-15 | Bhavnagri Veer General Counsel | Sale | −5,000 | $24.77 | $124K | 421,669 |
| 2021-09-15 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −5,000 | 112,300 | ||
| 2021-09-09 | WITTE OWEN N. Director | Sale | −5,000 | $25.54 | $128K | 221,182 |
| 2021-08-20 | WITTE OWEN N. Director | Sale | −5,000 | $23.70 | $119K | 231,182 |
Page 10 of 18 · 348 trades